Pediatric Gastroenterology and Nutrition Unit, Edith Wolfson Medical Center, Holon, Israel.
Tel Aviv University, Tel Aviv, Israel.
Gut. 2018 Sep;67(9):1726-1738. doi: 10.1136/gutjnl-2017-315866. Epub 2018 May 18.
Recent advances in basic and clinical science over the last 3 years have dramatically altered our appreciation of the role of diet in inflammatory bowel diseases (IBD). The marked increase in incidence of these diseases along with the important role of non-genetic susceptibility among patients with IBD has highlighted that these diseases have a strong environmental component. Progress in the field of microbiome and IBD has demonstrated that microbiome appears to play an important role in pathogenesis, and that diet may in turn impact the composition and functionality of the microbiome. Uncontrolled clinical studies have demonstrated that various dietary therapies such as exclusive enteral nutrition and newly developed exclusion diets might be potent tools for induction of remission at disease onset, for patients failing biologic therapy, as a treatment for disease complications and in reducing the need for surgery. We review these advances from bench to bedside, along with the need for better clinical trials to support these interventions.
过去 3 年来,基础和临床科学的最新进展极大地改变了我们对饮食在炎症性肠病(IBD)中的作用的认识。这些疾病的发病率显著增加,以及 IBD 患者中非遗传易感性的重要作用,突出表明这些疾病具有强烈的环境因素。在微生物组与 IBD 领域的进展表明,微生物组似乎在发病机制中起着重要作用,而饮食又可能反过来影响微生物组的组成和功能。未受控制的临床研究表明,各种饮食疗法,如肠内营养和新开发的排除饮食,可能是在疾病发病时诱导缓解、治疗生物治疗失败的患者、治疗疾病并发症以及减少手术需求的有效工具。我们从基础到临床回顾了这些进展,并需要更好的临床试验来支持这些干预措施。